Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeon BiodesignROCO:6499 -1.69%68 Days Payable is 10.02 as of Dec. 2025, which is 63% below its 10-year median of 26.74. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.08 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 796 Medical Devices & Instruments companies, Medeon Biodesign ranks worse than 97.99% on this metric.
The historical rank and industry rank for Medeon Biodesign's Days Payable or its related term are showing as below:
ROCO:6499'
s Days Payable Range Over the Past 10 Years
Min: 6.52 Med: 26.74 Max: 229.74
Current: 12.18
During the past 13 years, Medeon Biodesign's highest Days Payable was 229.74. The lowest was 6.52. And the median was 26.74.
ROCO:6499's Days Payable is ranked worse than 97.99% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs ROCO:6499: 12.18
Medeon Biodesign's Days Payable
declined
from Dec. 2024 (21.85) to Dec. 2025 (10.02).
It may suggest that Medeon Biodesignaccelerated paying its suppliers.
Medeon Biodesign Days Payable Related Terms
Medeon Biodesign Days Payable Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6499 vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Days Payable distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Medeon Biodesign's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medeon Biodesign (ROCO:6499) has a Days Payable of 10.02 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medeon Biodesign and its competitors. This is 63% below median its historical median of 26.74. Over the past decade, Medeon Biodesign's Days Payable has ranged from 6.52 to 229.74. According to the industry distribution chart, Medeon Biodesign ranks #780 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 98%.
Is Medeon Biodesign's Days Payable too high?
Medeon Biodesign's current Days Payable of 10.02 is 63% below median its 10-year median of 26.74. Over the past 10 years, this metric has ranged from a low of 6.52 to a high of 229.74. The Medical Devices & Instruments industry median Days Payable is 67.97. Medeon Biodesign's value of 10.02 is 85.3% below this industry median. Based on the distribution chart, Medeon Biodesign ranks #780 out of 796 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #780 out of 796 companies for Days Payable. This places Medeon Biodesign in the lower half of its industry. The industry median Days Payable is 67.97. Medeon Biodesign's value of 10.02 is 85.3% below this benchmark. Historically, Medeon Biodesign's own Days Payable has ranged from 6.52 to 229.74 over the past decade. While the company's 10-year median is 26.74 vs. the industry median of 67.97, Medeon Biodesign has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current Days Payable of 10.02 is 85.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medeon Biodesign and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current Days Payable is 10.02, which is 63% below median its own 10-year median of 26.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.08, compared to a current price of NT$69.80 — trading 34.8% below its estimated fair value. The current Days Payable is 10.02, which is 63% below median its 10-year median of 26.74 and 85.3% below the Medical Devices & Instruments industry median of 67.97. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Days Payable is 10.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$69.80 is trading 34.8% below its estimated GF Value™ of NT$107.08.
GuruFocus considers Medeon Biodesign to be Significantly Undervalued.
Key valuation signals for ROCO:6499:
Days Payable: 10.02 (63% below median its 10-year median of 26.74)
GF Value™: NT$107.08 vs. price of NT$69.80 (34.8% below fair value)
Industry Position: 85.3% below the Medical Devices & Instruments median (#780 of 796)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score
Get the complete analysis for ROCO:6499
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
